(WHTM) — A global campaign is marking Brain Awareness Week through Sunday, and Penn State professors are explaining some of ...

Explore Eli Lilly and Company stock: obesity drug tirzepatide sales +115%, new retatrutide diabetes data, and Kisunla ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Researchers are engineering a new class of miniature antibodies, called intrabodies, that can operate inside living cells to ...

The need for neurological care is especially acute in South Carolina, which has struggled to deliver timely, top-notch brain ...

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease ...

A widely used drug combination in anti-aging research may have a far more complicated effect on the brain than previously recognized. In mice, the treatment appeared to disrupt the cells responsible ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

The groups are calling for genotype-informed prevention and treatment strategies, APOE stratification in clinical trials, and related public policies.

A major new study finds people with type 1 diabetes face nearly three times the dementia risk. But lifestyle changes and new treatments offer real hope.

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...